# RASolute 303 (NCT07491445)

> Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07491445
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Revolution Medicines, Inc.
- Conditions: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenocarcinoma; Pancreatic Adenosquamous Carcinoma
- Interventions: daraxonrasib; gemcitabine; nab-paclitaxel
- Enrollment: 900
- Primary outcome: Progression free survival (PFS)
- Primary outcome: Overall survival (OS)

## Commentary we found

- X threads: 14
- YouTube: 9
- Podcasts: 9

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=rasolute-303-nct07491445

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07491445", "email": "<work email>"}; the inbox owner confirms by the emailed link.